AlphAIAlphAI — Financial news for AI agents
tradingview.com

Jefferies maintains Mesa Laboratories at Buy, raises price target to $150 from $125

Jefferies reiterated its Buy rating for Mesa Laboratories and increased its price target to $150 from $125, suggesting a 9.6% upside from the Nov 10 close of $136.91, according to the firm.

Original reporting
tradingview.com
Published Nov 10, 2026, 9:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Jefferies maintains Mesa Laboratories at Buy, raises price target to $150 from $125 — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The analyst's target raise signals confidence in the company's growth prospects, which could attract short‑term buyers.

02

Market read

Analyst upgrade may provide a modest catalyst for MESA, but overall market impact is limited.

03

What to watch

Potential supply‑chain constraints or regulatory risks not addressed in the note.

Relevance 4/10Novelty 5/10Timing: today

Background

Mesa Laboratories (MESA) is a specialty chemicals maker with recent volatility.

Market effects

Sector

May lift sentiment in the specialty chemicals sector.

Regional

Limited to U.S. small‑cap investors.

Global

Minimal.

Counterpoint

What could challenge this read

The target raise could be premature if upcoming earnings miss expectations.

Key entities

  • Analyst
    Jefferies

    Equity research firm issuing the rating upgrade.

  • Company
    Mesa Laboratories

    Specialty chemicals manufacturer.

Read at source← All news

Related articles

$MLABMedAI 8/10

Mesa Laboratories Inc (MLAB) Q2 2027 Earnings Call Highlights: Margin Expansion

Mesa Laboratories (MLAB) reported Q2 2027 earnings, highlighting margin expansion and strategic shifts. CEO Siddhartha Kadia discussed clinical genomics restructuring, aiming for profitability with a focus on pharmacogenomics and oncology. SDC grew 14.6% organically, while BPD saw an 8.2% decline due to timing issues. The company announced a $9.3 million savings plan, with $4.3 million reinvested. Full-year guidance is $250M-$255M revenue and $66M-$68M adjusted EBITDA.

finance.yahoo.com
$MLABMed

Mesa Labs (MLAB) Q2 2027 Earnings Call Transcript

Mesa Labs (MLAB) reported Q2 2027 earnings, highlighting 2.6% organic revenue growth, with Sterilization and Disinfection Control (SDC) up 14.6% and Calibration Solutions up 3.5%. Biopharmaceutical Development saw an 8.2% decline due to timing issues. The company announced cost-cutting measures in Clinical Genomics, reduced net leverage to 1.75x, and provided full-year guidance with revenues expected to grow 5-8%. A $40M share repurchase program was authorized.

finance.yahoo.com
$MLABHigh

Mesa Labs Revenue Rises 2.6%; Issues FY2027 Guidance

Mesa Labs reported Q2 FY2027 revenue of $62.3M, up 2.6% YoY, with net income of $4.3M. Adjusted EBITDA rose 21.1% to $17.3M. The company issued FY2027 guidance, expecting revenue of $250M-$255M and adjusted EBITDA of $66M-$68M. Mesa also announced a $40M share repurchase program.

tradingview.com
$MLABHighAI 8/10

Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces Second Quarter Fiscal Year 2027 Results and Issues First Full-Year Guidance Lakewood, Colorado , November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality

SEC EDGAR 8-K